Abstract
Introduction
Drugs with new mechanisms, in particular Pfizer' s oral JAK inhibitor
CP-690,550 and Chugai/Roche' s Actemra (tocilizumab), will launch for
rheumatoid arthritis and should offer advantages over current therapies, but
do not come without some safety signals. Late-stage pipeline launches will be
a major contributor to market growth from $7.4 billion in 2008 to $11.5
billion in 2018.
Scope of this research
- In-depth analysis of Phase II and III disease modifying drug candidates in
the rheumatoid arthritis pipeline
- Segmentation and analysis of the current rheumatoid arthritis pipeline by
developmental phase, drug class and company
- Insight and analysis of market potential including commercial opportunity,
epidemiology and discussion of unmet needs
- Focus on innovative early-stage drug development with assessment of future
treatment of rheumatoid arthritis
Research and analysis highlights
The shift from Western regions to countries in Eastern Europe and South
America is now a prominent feature of modern rheumatoid arthritis clinical
trials. This has led to variability in placebo and drug responses resulting in
higher failure rates. This will continue to be a difficult hurdle for drug
development in rheumatoid arthritis.
Pfizer' s JAK inhibitor CP-690,550 blazes the trail for small molecule kinase
inhibitors in rheumatoid arthritis. Despite efficacy being in line with
biologics, product positioning, safety and cost are key debatable issues for
uptake of this new drug upon launch in 2012. Datamonitor forecasts sales in
the seven major markets of $0.9 billion in 2018.
Pre-launch awareness, robust clinical data and marketing capability leads
Datamonitor to believe Actemra (tocilizumab; Roche/Chugai) will have a
significant impact on the market. Safety remains a question, but physicians
are willing to deal with issues highlighted in clinical trials. Datamonitor
expects Actemra to achieve blockbuster sales by 2015.
Key reasons to purchase this research
- Understand the major recent advances in the dynamic and constantly
evolving rheumatoid arthritis pipeline
- Evaluate the sales forecasts of key late-stage pipeline products to 2018
and understand new product positioning in this competitive market
- Assess key opinion leaders' views on the most advanced pipeline products
including Pfizer' s JAK inhibitor CP-690,550
| 
View Cart
